DelveInsight’s “Motor Neuron Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Motor Neuron Disease market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Motor Neuron Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Motor Neuron Disease: An Overview
Motor neuron diseases (MNDs) are an umbrella term used for a group of diseases that result in the progressive destruction of neurons and gradual deterioration of voluntary muscle function, leading to high mortality and morbidity. In general, Motor neuron diseases cause weakness without notable sensory symptoms or pain. The most common motor neuron disease is amyotrophic lateral sclerosis. Other motor neuron diseases include hereditary spastic paraparesis, spinobulbar muscular atrophy, and infectious motor neuron diseases.
Since the treatment of various motor neuron diseases and their mimics have markedly different treatments, accurate diagnosis is important. Motor neuron disease is usually diagnosed by a neurologist based on the symptoms and a physical examination. There’s no single test for motor neuron disease, but the diagnosis is often obvious from a person’s symptoms and physical examination by a neurologist.
Motor Neuron Disease Market Key Facts
-
A study by Yedavalli V.S.. et al. (2018) stated the average incidence of MNDs is 1–3 cases per 100,000. The prevalence of MND ranges from 1 to 9 cases per 100,000 worldwide. Of this group, amyotrophic lateral sclerosis (ALS) is by far the most common, comprising roughly 80%–90% of MND cases.
-
According to a study by Kab S. et al. (2017), in France, MND incidence was 2.72/ 100,000 person-years. Incidence peaked between 75 and 79 years of age and decreased thereafter.
-
Motor neuron disease affects around two in every 100,000 people in the UK annually. There are about 5,000 people living with the condition in the UK at any one time.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Motor Neuron Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Motor Neuron Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Motor Neuron Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Motor Neuron Disease Epidemiology Segmented by –
-
Prevalent Population of Motor Neuron Disease
-
Diagnosed and Treatable Population of Motor Neuron Disease
-
Type-specific Prevalent Population of Motor Neuron Disease
-
Age-specific Prevalent Cases of Motor Neuron Disease
Motor Neuron Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Motor Neuron Disease market or expected to get launched during the study period. The analysis covers the Motor Neuron Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Motor Neuron Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Motor Neuron Disease Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/motor-neuron-disease-market
Motor Neuron Disease Therapeutics Analysis
The principal aim of treatment is to reduce symptoms associated with different types of Motor Neuron Disease. The pipeline for Motor Neuron Disease is robust, with many key players working towards therapy development targeting Motor Neuron Disease and Amyotrophic Lateral Sclerosis.
Motor Neuron Disease Therapies covered in the report include:
-
Reldesemtiv
-
Tofersen
-
OAV-101
-
AMX0035
-
ION363
-
NurOwn
And many more
Some of the key companies in the Motor Neuron Disease therapeutics market include:
-
Cytokinetics
-
Biogen
-
Novartis
-
Amylyx Pharmaceuticals
-
Ionis Pharma
-
Brainstorm Cell Therapeutics
And many others
As per DelveInsight, the improved understanding of the disease, better trial designs, and an increase in the number of RCT’s will lead to the development of better treatment options for Motor Neuron Disease in the coming years.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/motor-neuron-disease-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Motor Neuron Disease Competitive Intelligence Analysis
4. Motor Neuron Disease Market Overview at a Glance
5. Motor Neuron Disease Disease Background and Overview
6. Motor Neuron Disease Patient Journey
7. Motor Neuron Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Motor Neuron Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Motor Neuron Disease Unmet Needs
10. Key Endpoints of Motor Neuron Disease Treatment
11. Motor Neuron Disease Marketed Products
12. Motor Neuron Disease Emerging Drugs and Latest Therapeutic Advances
13. Motor Neuron Disease Seven Major Market Analysis
14. Attribute Analysis
15. Motor Neuron Disease Market Outlook (In US, EU5, and Japan)
16. Motor Neuron Disease Access and Reimbursement Overview
17. KOL Views on the Motor Neuron Disease Market
18. Motor Neuron Disease Market Drivers
19. Motor Neuron Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/motor-neuron-disease-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Motor Neuron Disease Pipeline Insight
DelveInsight’s “Motor Neuron Disease Pipeline Insight, 2022” report outlays comprehensive insights into the present clinical development scenario and growth prospects across the Motor Neuron Disease market. The report embraces in-depth commercial and clinical assessments of the Motor Neuron Disease pipeline products from the pre-clinical developmental phase to the marketed phase, along with the key companies working in the therapeutics segment.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/